Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Headline
In this conversation, Amy Lee, president and chief operating officer at Nantucket Cottage Hospital, shares how telehealth is transforming patient care on the…
Headline
An executive order issued by the White House Oct. 19 directs the Department of Health and Human Services, through the National Institutes of Health, to…
Headline
The second listening session in the AHA’s series on disability health will focus on community partnerships and is scheduled for Oct. 28 at 1 p.m. ET. These…
Headline
In this conversation, Brian Peters, CEO of the Michigan Health & Hospital Association, explores the connection between health disparities, healthcare costs…
AHA Cyber Intel
While we may feel inundated with alarming news about escalating cyber threats against healthcare organizations, there is also some good news. Let’s explore how…
Headline
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, clinical data and labeling for…